Corticosteroids in Hyperinflammatory Phenotype of Critical Illness
A legfontosabb adatok
- Ki végzi
- Bin Du
- Hol
- Kína11 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2026. ápr. 15.
- Várható befejezés
- 2028. jún. 1.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Methylprednisolone (MP)
- Placebo
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Onset of ARDS and/or sepsis within 72 hours; ARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O; Sepsis is defined according to Sepsis-3 as suspected or confirmed infection accompanied by an acute increase in SOFA score of ≥ 2 points attributable to infection
- Requirement for invasive mechanical ventilation
- Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.50 using the clinical classifier
- Written informed consent provided by the participant or a legally authorised representative
Ki nem vehet részt
- Systemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period.[16]
- Solid-organ transplantation or allogeneic stem-cell transplantation
- Concurrent participation in another interventional clinical trial
- Severe congenital or acquired immunodeficiency, including HIV infection
- Brain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with a life expectancy of less than 6 months
- Life-threatening active fungal infection or active tuberculosis
- Known hypersensitivity to corticosteroids
- Neuromuscular disease that substantially impairs spontaneous breathing
- Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate
- High vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min
- A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment
- Pregnancy or lactation
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Does methylprednisolone improve organ function compared with placebo? * Does methylprednisolone reduce the risk of mortality within 30 days?
Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety.
Participants will:
* Receive high-dose methylprednisolone, low-dose methylprednisolone, or placebo every 12 hours for the first 3 days * Be reassessed on Day 4 based on their inflammatory status If the hyperinflammatory phenotype persists, the treatment dose will be reduced by half and continued until Day 7 or ICU discharge, whichever occurs first If the patient transitions to a hypoinflammatory phenotype, the study treatment will be discontinued * Be monitored daily in the intensive care unit for organ function, inflammatory status, and need for organ support * Be followed for up to 30 days after randomization to assess survival and recovery
A vizsgálat 3 csoportja
- high dose methylprednisolone groupA vizsgált kezelés
Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Kezelés: Methylprednisolone (MP)
- low dose methylprednisolone groupA vizsgált kezelés
Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Kezelés: Methylprednisolone (MP)
- placebo groupPlacebo, összehasonlításként
Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial
- A regiszteradat frissítve
- 2026. november 18.